



FOR IMMEDIATE RELEASE

Thursday, November 6, 2008

**Transgenomic to Present at Rodman & Renshaw
10th Annual Healthcare Conference**

Omaha, NE, November 6, 2008 – Transgenomic (OTC-Bulletin Board: TBIO.OB) today announced that Craig Tuttle, President and CEO of Transgenomic, will present at the Rodman & Renshaw 10th Annual Healthcare Conference to be held November 10-12, 2008 at the New York Palace Hotel in New York City. Mr. Tuttle and Debra Schneider, Chief Financial Officer, will be available to respond to questions during the presentation.

Event: Rodman & Renshaw 10th Annual Healthcare Conference
Date: Wednesday, November 12, 2008
Time: 2:00 p.m. ET
Place: New York Palace Hotel, Adams (4th Floor)

The presentation will be webcast live and can be accessed through the provided link:

<http://www.wsw.com/webcast/rrshq14/tbio.ob/>

About Transgenomic

Transgenomic (OTC-Bulletin Board: TBIO.OB) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis. The Company provides products and services in the fields of pharmacogenomics and pharmacogenetics.

Product offerings include the WAVE® DHPLC Systems and associated consumables specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. With broad applicability to genetic research, over 1600 systems have been shipped to customers in more than 30 countries. The SURVEYOR® Mutation Detection Kits and SURVEYOR Check-It Kit provide reagents and protocols for the detection of mutations in DNA. In addition, HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared to manual methods.

Service offerings include the Transgenomic Clinical Reference Laboratory, which provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases. Transgenomic Genomic Research Services is a CRO for pharmacogenomic, translational research and clinical trials. For more information about the innovative systems, products and services offered by Transgenomic, please visit: www.transgenomic.com.



Transgenomic Cautionary Statements

Certain statements in this press release constitute “forward-looking statements” of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management’s current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic’s reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.